Profilo
Nuket Desem worked as a Senior Manager of Development & Regulatory Affairs at Alterity Therapeutics Ltd., Vice President of Clinical & Regulatory Affairs at Spinifex Pharmaceuticals Pty Ltd., Principal at CSL Ltd., Senior Associate at Kendle Pty Ltd., Development Director at Percheron Therapeutics Ltd., and Director of Clinical & Regulatory Affairs at Percheron Therapeutics Ltd.
and Paranta Biosciences Ltd.
Desem holds an MBA from Monash University and an undergraduate degree from LaTrobe University.
Precedenti posizioni note di Nuket Desem
| Società | Posizione | Fine |
|---|---|---|
| PERCHERON THERAPEUTICS LIMITED | Chief Tech/Sci/R&D Officer | 05/05/2023 |
| PERCHERON THERAPEUTICS LIMITED | Corporate Officer/Principal | 31/08/2010 |
| ALTERITY THERAPEUTICS LIMITED | General Counsel | - |
Paranta Biosciences Ltd.
 Paranta Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Paranta Biosciences Ltd. engages in the research and development of novel biotherapeutic. t develops PB01 (recombinant human follistatin-288) for the treatment of fibrotic and inflammatory diseases. The company was founded in 2011 and is headquartered in Richmond, Australia. | Chief Tech/Sci/R&D Officer | - |
| CSL LIMITED | Corporate Officer/Principal | - |
Formazione di Nuket Desem
| Monash University | Masters Business Admin |
| LaTrobe University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| CSL LIMITED | Health Technology |
| PERCHERON THERAPEUTICS LIMITED | Health Technology |
| ALTERITY THERAPEUTICS LIMITED | Health Technology |
| Aziende private | 3 |
|---|---|
Spinifex Pharmaceuticals Pty Ltd.
 Spinifex Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology Spinifex Pharmaceuticals Pty Ltd. discovers and develops new drugs for the treatment and management of pain. The firm conducts medicinal chemistry and drug discovery activities, preclinical and early-phase clinical studies before seeking a partnership with pharmaceutical company to complete clinical development, file for regulatory approval, and carry out marketing activities. The company was founded in June 2005 and is headquartered in Preston, Australia. | Health Technology |
| Kendle Pty Ltd. | |
Paranta Biosciences Ltd.
Paranta Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Paranta Biosciences Ltd. engages in the research and development of novel biotherapeutic. t develops PB01 (recombinant human follistatin-288) for the treatment of fibrotic and inflammatory diseases. The company was founded in 2011 and is headquartered in Richmond, Australia. | Health Technology |
- Borsa valori
- Insiders
- Nuket Desem
